Search for: "Allergan plc" Results 1 - 20 of 34
Sorted by Relevance | Sort by Date
RSS Subscribe: 20 results | 100 results
6 Apr 2016, 7:37 pm by Consuella Pachico
Pfizer Inc. and Allergan PLC withdrew their planned $160 billion merger, ending what would have been the largest so-called inversion transaction. [read post]
19 Feb 2020, 1:03 pm by Doyle, Barlow & Mazard PLLC
Federal Trade Commission (“FTC”) raising concerns that the divestiture of Allergan plc’s (“Allergan”) pipeline drug, brazikumab, will not succeed unless the FTC addresses AbbVie’s use of rebate walls. [read post]
6 May 2020, 1:51 pm by Doyle, Barlow & Mazard PLLC
’s (“AbbVie”) $63 billion acquisition of Allergan plc (“Allergan”) on the condition that the merging parties divest three minor products. [read post]
21 Dec 2015, 3:00 am by Paul Caron
Marian (UC-Irvine), Inversions and Competitiveness: Reflections in the Wake of Pfizer/Allergan: The recent announcement that Pfizer Inc. has reached a merger agreement with Allergan PLC , with the combined entity being tax-resident in Ireland, is a good occasion to reconsider U.S. policy options... [read post]
5 Jun 2018, 8:04 am by Howard Bashman
“Judges Criticize Allergan’s Use of Mohawk Tribe’s Sovereignty”: Susan Decker of Bloomberg News has a report that begins, “Allergan Plc faced a skeptical appeals court Monday as the company defended its use of an American Indian tribe’s sovereign immunity to avoid challenges to its patents from generic-drug makers. [read post]
9 Mar 2014, 9:31 pm by Patent Docs
Actavis plc et al. 2:14-cv-00188; filed March 6, 2014 in the Eastern District of Texas • Plaintiff: Allergan, Inc. [read post]
13 Dec 2016, 4:15 am by Gene Quinn
Last week the Patent Trial and Appeal Board (PTAB) of the United States Patent and Trademark Office (USPTO) instituted six separate inter partes reviews (IPRs) against patents owned by Allergan plc, which cover RESTASIS®. [read post]
19 Apr 2015, 9:56 pm by Patent Docs
• Defendants: Allergan, Inc.; Actavis, PLC.; Allergan Sales, LLC Infringement of U.S. [read post]
30 Nov 2015, 6:11 am
The situation, which ultimately resulted in the acquisition of Allergan by Actavis plc, included a novel structure that involved a “partnership” between Valeant and the investment fund Pershing Square. [read post]
30 Jan 2019, 5:06 am by Sara E. Teller
Besides Purdue Pharma LP, the list of defendants named in NYC’s suit includes long-time opioid manufacturers Allergan Plc, Endo International Plc, Johnson & Johnson, and Teva Pharmaceutical Industries Ltd., and distributors AmerisourceBergen Corp, Cardinal Health Inc and McKesson Corp. [read post]
On November 17, 2014, Allergan, Inc. announced a $66 billion merger agreement with Actavis plc, thwarting the pending $53 billion bid for Allergan by Valeant Pharmaceuticals International Inc. [read post]
26 Sep 2017, 12:46 pm by Associated Press
., Janssen Pharmaceuticals Inc. and Allergan PLC, filed a brief Friday saying they’ve complied with the U.S. [read post]
21 Dec 2016, 7:18 am by Gene Quinn
The Patent Trial and Appeal Board (PTAB) of the United States Patent and Trademark Office (USPTO) recently instituted six separate inter partes reviews (IPRs) against patents owned by Allergan plc (NYSE: AGN), which cover RESTASIS® (Cyclosporine Ophthalmic Emulsion) 0.05%. [read post]
15 Nov 2015, 9:32 pm by Patent Docs
.; Allergan PLC Infringement of U.S. [read post]
24 Feb 2018, 10:12 am by Lawrence B. Ebert
CSR PLC, 771 F.3d 1336, 1342 (Fed. [read post]
8 Nov 2016, 11:53 pm by Kevin LaCroix
  First, on November 4, plaintiffs’ lawyers filed a securities class action lawsuit in the Central District of California against Allergan plc, Allergan’s predecessor company Actavis plc, and certain of its Allergan’s directors and officers. [read post]
23 Nov 2015, 2:05 pm by Ben Vernia
Sales LLC, a subsidiary of pharmaceutical manufacturer Warner Chilcott PLC, has agreed to plead guilty to a felony charge of health care fraud, the Justice Department announced today. [read post]
21 Mar 2015, 6:26 am by Lawrence B. Ebert
Actavis plc (NYSE:ACT), No. 1:14-cv-00882 (D. [read post]
16 Nov 2017, 6:17 am
Company Name Annual Director Retainer Regeneron Pharmaceuticals $2,074,085 Tesla $1,664,928 The Goldman Sachs Group $575,000 $550,000 Celgene Corporation $524,871 Reynolds American $496,480 Valeant Pharmaceuticals International $475,000 Allergan PLC $450,000 Everest Re Group, Ltd. $447,030 Oracle $429,172 (more…) [read post]